The landing price of Cabozantinib in 2025

Cabozantinib is a multi-target tyrosine kinase inhibitor that mainly achieves anti-tumor effects by inhibiting signaling pathways related to tumor angiogenesis and cancer cell proliferation. It is one of the oral targeted drugs that has attracted much attention internationally in recent years and is widely used in the treatment of various solid tumors such as advanced renal cell carcinoma, liver cancer, and thyroid cancer. Due to its high research and development costs and high technical barriers, the original drug cabozantinib has not yet been officially launched in mainland China. It is currently only available through channels in Hong Kong, China and some overseas countries. Therefore, its price has become the focus of patients' attention.

Currently in the Hong Kong market, the common specifications of cabozantinib include20mg 30 tablets, 40mg 30 tablets and 60mg*30 tablets, with each box selling for about 50,000 yuan (the specific price may fluctuate due to exchange rates and supply chain factors). In overseas markets, Japan, Europe, Türkiye and other regions have approved the sale of cabozantinib, and some countries provide both tablets and capsules. Generally speaking, the European version of tablets is sold for about 30,000 yuan per box, while the price of capsules is slightly higher, about 40,000 yuan. Although these prices are high, the drug is still recognized by cancer patients and doctors because of its extensive clinical efficacy in international clinical trials.

In recent years, with the maturity of generic drug production technology, many countries have launched affordable alternative versions of cabozantinib. Among them, the Indian, Bangladeshi and Laos versions of cabozantinib are more cost-effective and have the same ingredients as the original drug. The main difference lies in packaging and production standards. For example, the specification of cabozantinib produced by Lucius Pharmaceuticals in Laos is 20mg*90 tablets, and the price per box may be less than RMB 1,000. Although generic drugs are close to original drugs in terms of pharmacological activity and clinical effects, patients need to purchase them through formal channels and use them under the guidance of a doctor to ensure stable efficacy and safety.

Reference:https://en.wikipedia.org/wiki/Cabozantinib